2 weeks Ago By ABMN Staff
Wellington Management Group LLP reduced its stake in shares of CareDx, Inc ( NASDAQ:CDNA – Free Report ) by 14.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 165,362 shares of the company’s stock after selling 28,360 shares during the period.
Wellington Management Group LLP owned about 0.31% of CareDx worth $3,540,000 as of its most recent filing with the SEC. Several other institutional investors and hedge funds have also recently modified their holdings of CDNA.
Quarry LP purchased a new stake in CareDx in the 3rd quarter valued at $27,000. Plato Investment Management Ltd grew its stake in shares of CareDx by 34.1% in the 4th quarter.
Plato Investment Management Ltd now owns 5,390 shares of the company’s stock worth $116,000 after acquiring an additional 1,370 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of CareDx in the third quarter valued at about $271,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of CareDx by 41.
5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company’s stock valued at $200,000 after purchasing an additional 2,742 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in CareDx during the fourth quarter worth about $208,000.
CareDx Price Performance Shares of NASDAQ CDNA opened at $18.81 on Friday. The stock has a market capitalization of $1.
04 billion, a PE ratio of -6.97 and a beta of 2.18.
CareDx, Inc has a one year low of $7.42 and a one year high of $34.84.
The business’s fifty day moving average price is $20.23 and its 200-day moving average price is $22.74.
Analyst Ratings Changes CDNA has been the subject of several analyst reports. Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and decreased their price objective for the company from $28.00 to $24.
00 in a research note on Wednesday, January 15th. Stephens reiterated an “overweight” rating and set a $40.00 price target on shares of CareDx in a report on Thursday, February 27th.
HC Wainwright reduced their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd.
Finally, StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock.
Based on data from MarketBeat, CareDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83. Get Our Latest Stock Report on CDNA About CareDx ( Free Report ) CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Read More Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter .
.
